Key result
Diabetes linked to greater prostate cancer aggressiveness in lean white and Hispanic men, unlike Black men.
Why the study?
Conflicting literature exists regarding the association between obesity, diabetes, and prostate cancer development, prompting an evaluation of their relationship with cancer aggressiveness at diagnosis.
Are obesity and diabetes associated with prostate cancer aggressiveness at diagnosis?
Cohort (n=22,554)
Are obesity and diabetes associated with prostate cancer aggressiveness at diagnosis?
Effect estimate: OR 1.40 (95% CI 1.18-1.66)
p-value: p=<0.001
Obesity and diabetes are associated with increased risk of aggressive prostate cancer at diagnosis, with the effect of diabetes varying by race and obesity status.
Should not yet change practice regarding diabetes in prostate cancer risk models; leaves open racial and obesity-related variations for dedicated research.
Introduction Prostate cancer is the most common cancer in men the United States and Louisiana ranks third for prostate cancer mortality rates in the US. With over 40 % adult obesity rates, Louisiana ranks fourth among states for obesity rates. There is conflicting literature on the association between obesity, diabetes and PCa development. We aim to assess if there is an association between obesity, diabetes and PCa aggressiveness at the time of diagnosis, and if this association is modified by race or obesity status. Methods Cases of primary invasive locoregional prostate cancer diagnosed in 2011-2020 were obtained from Louisiana Tumor Registry. PCa aggressiveness was defined in accordance with the TNM stage and Gleason score. Obesity was defined as BMI of 30 or higher, and type 2 diabetes was identified using ICD-10 codes. Linear trends were assessed with Cochran-Armitage Trend tests and highly aggressive disease at diagnosis was modeled using logistic regression. Analyses were performed overall and stratified by race. Results The study included 22,554 cases. Most cases were white (62%), while 35% were Black, and 2% were Hispanic. The overall distribution of PCa aggressiveness was low (23%), intermediate (47%), and high (30%). PCa aggressiveness was significantly associated with older age, Black race, obesity, and diabetes (p<.001). Stratified by race, the relationship between diabetes and aggressiveness was significant among whites (p<.001) and Hispanics (p=0.037) but not Blacks (p=0.398). In multivariable models controlling for age and obesity, diabetes was significantly associated with high PCa aggressiveness among lean white (OR=1.40 (1.18,1.66)) and Hispanic (OR = 2.68 (1.13,6.36)) men, but not among lean (OR=1.08 (0.90,1.29)) or obese (OR= 0.94 (0.78,1.12)) Black men. Conclusion We found that obesity is associated with increased risk of aggressive PCa in both Caucasian and Black men, and Obesity and Diabetes are risk factors that interact in PCa patients. Our ongoing research studies are aimed at assessing the contribution of social, environmental, behavioral, dietary and metabolic risk factors with a special emphasis on epigenetic and metabolic reprogramming for aggressive PCa within the Louisiana Cohort. Citation Format: Hari K. Koul, Denise danos, Yong yi, Augusto Ochoa, Lucio Miele, Xio-Cheng Wu. The association between obesity, diabetes and prostate cancer aggressiveness in Louisiana Cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3629.
No takes yet. Share an insight, caveat, or question.
Koul et al. (2026) conducted a cohort in Prostate cancer (n=22,554). Obesity and diabetes vs. Non-obese and non-diabetic was evaluated on Prostate cancer aggressiveness at diagnosis (OR 1.40, 95% CI 1.18-1.66, p=<0.001). Diabetes was significantly associated with high prostate cancer aggressiveness in lean white (OR 1.40; 95% CI 1.18-1.66) and Hispanic men (OR 2.68; 95% CI 1.13-6.36), but not in Black men.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: